Masimo Corp. has urged a California federal judge to reject Apple’s bid to erase a US$634 million patent-infringement verdict over Apple Watch heart-rate alerts, arguing trial evidence supported the ...

Despite a whopping $634 million patent infringement victory against Apple, Masimo is showing signs of weakness in its underlying fundamentals. According to Benzinga Edge's Stock Rankings data, ...

While headlines celebrated the patent infringement verdict, exclusive Benzinga Edge’s Stock Rankings data reveals that Masimo's quality score has tumbled to 10.43, placing it in the bottom tier of ...

Masimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company’s headquarters. At the event, Masimo’s management team provided an update on the Company’s long-term strategy, including the ...

Fintel reports that on November 24, 2025, BTIG reiterated coverage of Masimo (NasdaqGS:MASI) with a Buy recommendation. Analyst Price Forecast Suggests 26.03% Upside As of November 17, 2025, the ...

What just happened? Apple has been dealt a blow in its long-running patent battle against Masimo after a court ordered Cupertino to pay the health tech firm $634 million. The decision came on the same ...

A federal jury in the U.S. District Court for the Central District of California has ruled that Apple must pay $634 million to Masimo for allegedly infringing on a patent covering ‌blood-oxygen ...

A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen-monitoring technology. Reuters reports the jury found ...

The legal woes of the Apple Watch are continuing, as Apple has been hit with a $634 million verdict in a trial over alleged infringement of Masimo's blood oxygen monitoring patents. Masimo has ...

Nov 14 (Reuters) - A federal jury in California said on Friday that Apple (AAPL.O), opens new tab owes medical-monitoring technology company Masimo (MASI.O), opens new tab $634 million for infringing ...